Nirsevimab to Reduce Infant Morbidity From Respiratory Syncytial Virus

• 2024

  Log in to bookmark this resource.

  Log in
• Bahaa Abu-Raya; Joanne Langley; Pascal Lavoie
PMID: 39353638DOI: https://dx.doi.org/10.1503/cmaj.240780

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article describes how nirsevimab, a long-acting monoclonal antibody, helps prevent respiratory syncytial virus (RSV) infections in infants. RSV is a common virus that can cause serious illness in young children. Nirsevimab works by blocking the virus and is more effective than the older treatment, palivizumab. It is recommended for infants entering their first RSV season and those at high risk of severe disease. The article also mentions safety information and ongoing efforts to make nirsevimab widely available across Canada through public health programs.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Canada; Child; Infant; Infant, Newborn; Morbidity; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vaccination; Vaccines; Immunization Programs; Antibodies, Monoclonal, Humanized

Institutions: Dalhousie University; University of British Columbia

---

More like this

Surge Capacity Principles: Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement 2014 · University of Minnesota, The Hebrew University of Jerusalem, George Washington University, University of British Columbia, Sharp Healthcare, Allina Health Care Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper 2021 · University of Parma, University of British Columbia, University of Florence, Association Française de Pédiatrie Ambulatoire (AFPA), Launceston General Hospital, University of Tasmania "I Believe This Team Will Change How Society Views Youth in Disasters": The EnRiCH Youth Research Team: A Youth-Led Community-Based Disaster Risk Reduction Program in Ottawa, Canada 2021 · University of Ottawa, University of British Columbia, Canadian Red Cross

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---